RenovoRx Inc (NAS:RNXT)

Q2 2025 RenovoRx Inc Earnings Call Transcript

Aug 14, 2025 / 08:30 PM GMT

Release Date Price: $1.24 (+1.64%)

Transcript 8-K10-Q

Key Points

Positve

RenovoRx Inc (RNXT) achieved over $400,000 in sales in Q2 2025 without a dedicated sales and marketing team, indicating strong market demand.
The company's proprietary transarterial micro perfusion therapy platform (TAM) is designed to optimize drug concentration at tumor sites, minimizing systemic exposure and toxicities.
The independent Data Monitoring Committee (DMC) recommended continuing the phase 3 Tiger PAC trial, suggesting confidence in potential positive outcomes.
RenovoRx Inc (RNXT) has launched a multi-center postmarketing registry study called PANTHER to evaluate the safety and effectiveness of RenovoCas in real-world settings.
The company ended Q2 2025 with $12.3 million in cash and cash equivalents, which is expected to fully fund ongoing commercial scale-up efforts and the completion of the phase 3 trial.

Negative

Research and development expenses were $1.4 million for Q2 2025, reflecting ongoing costs associated with clinical and regulatory activities.
Selling, general, and administrative expenses remained high at approximately $1.5 million, unchanged from the previous year.
The decision to defer publishing the second interim data from the Tiger PAC trial may raise concerns about transparency and trial progress.
The company is still in the early stages of commercialization, with a need to build a sales and marketing infrastructure to sustain growth.
RenovoRx Inc (RNXT) faces the challenge of expanding its market presence and achieving profitability in a competitive oncology landscape.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RNXT.OQ - RenovoRx Inc
Q2 2025 RenovoRx Inc Earnings Call
Aug 14, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon. I'll be your conference call operator today. Please note that today's call is being recorded, and all participants other than management are in a listen-only mode. There will be a Q&A session following management's presentation. I will now turn the call over to Walter Pinto, managing director of KCSI KCSA Strategic Communications. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good afternoon. Welcome everyone to the Renovare 2nd quarter 2025 conference call. I'm joined today by Renovare's leadership team, including Dr. Ramta Aga,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.